This phenomenon may provide insight into the mechanisms by which the CSF1R inhibitor could benefit ALS patients in clinical trials [52], as these drugs may selectively deplete overactive microglia while preserving phagocytic DAM. The gene discussed is CSF1R; the disease is amyotrophic lateral sclerosis.